Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC), relative to a 7-valent pneumococcal conjugate vaccine (7vPnC) when given concomitantly with routine vaccines in Korea.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT00689351
Study type Interventional
Source Wyeth is now a wholly owned subsidiary of Pfizer
Contact
Status Completed
Phase Phase 2
Start date June 2008
Completion date December 2009

See also
  Status Clinical Trial Phase
Completed NCT01521897 - Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan) N/A
Completed NCT03098628 - Trial of Simplified Pneumococcal Vaccination in Vietnam II Phase 2/Phase 3
Active, not recruiting NCT06337643 - A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine Phase 1
Recruiting NCT03046134 - Burden of Hospitalized Pneumonia in Korea COPD Population N/A
Recruiting NCT06181656 - Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
Completed NCT05721092 - Assessment of Knowledge on Pneumococcal Vaccination Among Diabetologists in India
Completed NCT05788510 - Pneumococcal Vaccination in Patients With Anti-TNF Alpha Therapy